AbCellera Biologics Inc.
ABCL
Rank in Stocks
#4171
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Share Price
$11.87
Market Cap
$3.85B
Change (1 day)
0.59%
Change (1 year)
112.34%
Country
CA
Trade AbCellera Biologics Inc. (ABCL)
Category
Healthcare
P/S ratio for AbCellera Biologics Inc. (ABCL)
P/S ratio as of October 2026 TTM: 57.09
According to AbCellera Biologics Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 57.09. At the end of 2023 the company had a P/S ratio of 43.42.
P/S ratio history for AbCellera Biologics Inc. from 2018 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 57.09 | 90.86% |
| 2024 | 29.91 | -31.12% |
| 2023 | 43.42 | 629.95% |
| 2022 | 5.95 | -43.40% |
| 2021 | 10.51 | -77.40% |
| 2020 | 46.51 | -94.05% |
| 2019 | 781.63 | -22.42% |
| 2018 | 1.01K | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | -82.44% |
US
|
|
| 40.55 | -28.96% |
US
|
|
| 3.96 | -93.06% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -82.23% |
NL
|
